Kiwi....looking forward, isn’t this patent dispute limited to the marine indication..I.e...over 500 tgs? If so the market isn’t that large.. So looking forward, how can amarin keep generics from entering the reduce it indication, i.e., 150-500 Tgs with cv reduction labeling? Isn’t that what we care about the most?
Absolutely seek settlement. I agree with the posters who have been advocating settle and sell. As a warrior in the legal realm, I still believe that peace is better than war, and only go to war if there is no other choice.
Market Data 
Markets 
AI
